Skip to main content
OpenTrials
Completed

NCT Number: NCT06188910

Neurofeedback and Nomophobia in Young Adults

Introduction: Given the growing increase in addiction to social networks and smartphone use in young people and its implications for health, it is necessary to investigate effective interventions for the appropriate use of these technologies and coping with possible signs of addiction.

Objective: To evaluate the effect of an intervention based on neurofeedback techniques on anxiety and other disorders associated with problematic use of mobile phones and the internet in young adults.

Methodology: Randomised controlled clinical trial with two parallel groups: an intervention group (IG) and a control group (CG). The study population will be young adults aged 18-30 years. A sample size of 40 participants has been estimated, 20 in each group to detect a difference of 3.9 points or more on the DASS-21 anxiety questionnaire.

All participants will receive an educational workshop on the responsible use of new technologies and the promotion of healthy lifestyles. The IG, in addition to this educational workshop, will receive 25 neurofeedback sessions during 12 weeks, 2-3 sessions/week with the MUSE neurofeedback device.

A baseline and 3-month post-intervention assessment will be conducted for both groups to study change variables related to smartphone addiction (Smartphone Addiction Scale-Short Version (SAS-SV)), nomophobia (Nomophobia Questionnaire (NMP-Q)), depression, anxiety and stress (Depression, Anxiety and Stress Scale 21-item (DASS-21)) and sleep quality.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Salamanca

Salamanca, 37007, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have one or more mobile devices such as smartphones.
  • Have a compatible mobile device to install and use the Muse: EEG Meditation & Sleep application.
  • Be fully functional.
  • Willingness to voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

  • History of severe psychiatric disorders (such as schizoaffective disorders, bipolar disorder, major depressive episode with symptoms or other non-organic psychotic disorders) requiring psychiatric treatment in the 6 months prior to study entry.
  • History of brain injury or other problems contraindicating the use of neurofeedback.

Treatment and study plan

Neurofeedback

Other

Conducting neurofeedback sessions guided by a researcher

Other names: Biofeedback

Health education

Other

Health education on mobile phone addiction

Primary outcomes

  1. Anxiety

    Time frame: Baseline, 3-months

    Anxiety evaluated through Depression, Anxiety and Stress Scale 21-item (DASS-21). Minimum 0 - maximum 63

Secondary outcomes

  1. Nomophobia

    Time frame: Baseline, 3-months

    Nomophobia evaluated through Nomophobia Questionnaire (NMP-Q). Minimum 20 - maximum 140

  2. Sleep Quality

    Time frame: Baseline, 3-months

    Sleep quality evaluated through Atenas questionnaire. Minimum 0 - maximum 24

Sponsors and collaborators

Lead sponsor

University of Salamanca

Other

Collaborators

  • Gerencia Regional de Salud de Castilla y Leon
  • Instituto de Investigación Biomédica de Salamanca

Registry information

Official study title

Effectiveness of a Neurofeedback Intervention on Symptoms of Anxiety and Psychological Distress Associated With Smartphone Use in Young Adults

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Jan 3, 2024
Registry last updated
Sep 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.